Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Caregivers for people with dementia are more likely to report having at least one modifiable risk factor linked to developing dementia.

The FDA plans to approve selected high-priority drug application submissions in 1 to 2 months rather than 10 to 12.

Research on the preferences of patients with AD, caregivers, and health care providers may be influenced by pharmaceutical company sponsorship.

Automated data review assists in identifying problematic opioid usage, outperforming manual methods in sensitivity and positive predictive value.

Mortality rates associated with calciphylaxis are lower than previously observed, with rates of 28.88% at 1-year and 29.92% at 2-years.

Rates of proven drug hypersensitivity reactions are comparable between children with and without inborn errors of immunity (IEI).

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Patients who received oral tranexamic acid 500 mg daily for 3 months had reduced melasma severity and systemic inflammation markers.

The intensity of CKD-aP is linked to levels of systemic inflammation, with reductions in these levels seen with difelikefalin treatment.

Results of an autopsy-based study revealed that sudden cardiac death and multiorgan pathology may be more closely linked to SSc than previously thought.

Experienced epidemiologist Dr Fiona Havers resigned from the CDC due to her lack of confidence in the current leadership.